as-605240 and Hepatitis

as-605240 has been researched along with Hepatitis* in 1 studies

Other Studies

1 other study(ies) available for as-605240 and Hepatitis

ArticleYear
Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis.
    European journal of medicinal chemistry, 2019, Oct-01, Volume: 179

    A series of (1,2,4)triazole[4,3-a]pyridine (TZP) derivatives have been designed and synthesized. Compound 8d was identified as having the most potent inhibitory activity on NO release in response to lipopolysaccharide (LPS) stimulation and inhibition of the migration induced by MCP-1 protein on RAW264.7 macrophages. Based on the screening data, an immunofluorescence assay and a real-time qPCR assay were conducted, indicating that compound 8d suppressed NF-κB p65 translocation and expression of inflammatory genes by concanavalin A (Con A)-induced RAW264.7 macrophages. More importantly, 8d also exhibited potent efficacy, alleviating Con A-induced hepatitis by downregulating the levels of plasma alanine transaminase (ALT), aspartate transaminase (AST) and inflammatory infiltration in a mouse autoimmune hepatitis (AIH) model. In addition, the flow cytometry (FCM) data showed that compound 8d inhibited the accumulation of MDSCs in the liver of Con A-induced mice. These findings raise the possibility that compound 8d might serve as a potential agent for the treatment of AIH.

    Topics: Animals; Cell Survival; Cells, Cultured; Concanavalin A; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Female; Hepatitis; Humans; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Molecular Structure; Nitric Oxide; Pyridines; RAW 264.7 Cells; Structure-Activity Relationship; Triazoles

2019